# A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy

> **NCT05068921** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Cervical Cancer

## Interventions

- **DRUG:** TQB2858 injection

## Key facts

- **NCT ID:** NCT05068921
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-09
- **Primary completion:** 2023-05
- **Final completion:** 2023-07
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05068921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05068921, "A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignancy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05068921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*